BigCapital beta

Moscow Exchange · OZPH · IFRS

Ozon Pharmaceuticals: revenue, profit and cash flow

In 2025, Ozon Pharmaceuticals had revenue of ₽31.6B and a net profit of ₽6.17B, according to its consolidated IFRS statements. Here: 4 years of annual reports since 2022, each linked to the original document.

Revenue, 2025

₽31.6B+23.6%

change against 2024

Net profit
₽6.17B
attributable to shareholders · 19.5% of revenue
Earnings per share, 2025
₽5.44
Operating cash flow
₽3.25B
Capital expenditure
₽1.96B
Free cash flow
₽1.29B
operating cash flow minus capital expenditure
Net debt
₽8.97B
borrowings minus cash; leases not included
Dividends paid
₽1.07B
Total assets
₽53.2B
Equity
₽33.2B

Where the money goes

Of every ₽100 of revenue in 2025, Ozon Pharmaceuticals spent ₽52.3 on the cost of its products and services and ₽13.6 on running the business (₽11.9 of it on selling and administration); ₽5.9 went to income tax, ₽8.7 went to interest and other items, and ₽19.5 was left as net profit.

2025 · rubles · share of revenue
In 2025AmountOf revenue
Revenue₽31.6B100.0%
Cost of revenue−₽16.5B52.3%
Gross profit₽15.1B47.7%
Sales & admin−₽3.77B11.9%
Other operating−₽520M1.6%
Operating profit₽10.8B34.1%
Income tax−₽1.86B5.9%
Interest and other, net−₽2.75B8.7%
Net profit₽6.17B19.5%

Revenue and net profit

Revenue went from ₽19B in 2022 to ₽31.6B in 2025.

RevenueNet profit
Rubles, as reported (IFRS); years without a report are left out.

Earnings per share

Basic earnings per share went from ₽3.65 in 2022 to ₽5.44 in 2025.

Years · rubles per share, basic, adjusted for share splits

Number of shares

The weighted average number of ordinary shares went from 1.0B in 2022 to 1.14B in 2025.

Years · weighted average ordinary shares, as printed next to earnings per share

Operating cash flow, capex and free cash flow

Free cash flow (operating cash flow minus capital expenditure) was ₽1.29B in 2025, 4.1% of revenue. Negative in 2022.

Operating cash flowCapital expenditureFree cash flow
Rubles, as reported (IFRS); years without a report are left out.

What it owns and who paid for it

At the end of 2025, Ozon Pharmaceuticals had ₽53.2B of assets, ₽2.83B of it in cash. They were paid for by ₽11.8B of borrowings, ₽8.23B of other liabilities and ₽33.2B of shareholders' equity: equity is 62.4% of the assets.

End of 2025 · rubles · share of assets · sizes across years on a square-root scale

Net debt

Net debt (borrowings minus cash) was ₽8.97B at the end of 2025. That is 0.7 times its EBITDA of ₽12B (operating profit plus depreciation and amortisation).

Net debt
Rubles, as reported (IFRS); years without a report are left out.

Dividends paid

In 2025, Ozon Pharmaceuticals paid ₽1.07B in dividends, 17% of its net profit for the year.

Dividends paid
Rubles, as reported (IFRS); years without a report are left out.

Ozon Pharmaceuticals: annual figures

YearRevenueOperating profitNet profitBasic EPSOperating cash flowCapital expenditureFree cash flowNet debtDividends paidTotal assetsEquity
2025₽31.6B₽10.8B₽6.17B₽5.44₽3.25B₽1.96B₽1.29B₽8.97B₽1.07B₽53.2B₽33.2B
2024₽25.6B₽7.94B₽4.61B₽4.46₽5.83B₽2.46B₽3.37B₽9.95B₽1.5B₽49.5B₽25.3B
2023₽19.7B₽6.15B₽4.0B₽4.00₽4.66B₽602M₽4.06B₽8.66B₽1.63B₽34.1B₽17.1B
2022*₽19B₽5.5B₽3.65B₽3.65−₽994M₽562M−₽1.56B₽10.3B₽1.29B₽34.1B₽14.7B

* Taken from the comparative column of the next year's report: the year's own report was not available to us.

Original reports

Every figure on this page comes from the company's own annual statements. The documents, by year:

How to read these numbers

Source: annual financial statements published by Ozon Pharmaceuticals (links to the original documents above). Figures read from the documents by BigCapital.

For information only, not investment advice.

Language

EnglishBahasa IndonesiaDeutschEspañolFrançaisItalianoNederlandsPolskiPortuguêsTürkçeРусскийУкраїнська日本語한국어简体中文